Autonomix Medical (NASDAQ:AMIX) Raised to “Hold” at Zacks Research

Autonomix Medical (NASDAQ:AMIX) was upgraded by Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Other research analysts also recently issued reports about the stock. Maxim Group dropped their target price on shares of Autonomix Medical from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, May 18th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $2.00.

Autonomix Medical Price Performance

Shares of AMIX opened at $0.39 on Tuesday. The firm’s 50 day moving average is $0.38 and its 200-day moving average is $0.50. The stock has a market capitalization of $2.71 million, a P/E ratio of -0.11 and a beta of -1.43. Autonomix Medical has a 12-month low of $0.20 and a 12-month high of $2.64.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.